

which directly and indirectly affect the occurrence and distribution of malaria (10). Whether malaria will return as a major health threat likely depends on the size and fragmentation of the individual plantation areas. The required size of a plantation for the survival of the vector population is unclear, but large areas of plantation tend to offer dense vegetation and, therefore, high humidity and shade, which provide suitable environmental conditions for larval habitats, even during the dry season (8). Conversely, during the rainy season, conditions at the edges of fragmented forests, where human settlements are often located, become favorable for larval habitats, rendering villagers susceptible to the disease (6). In addition to changes in habitat and microclimate, social or political changes in the region may affect the transborder movement of malaria into Thailand with consequences for potential reemergence (7).

Although the association between rubber plantations and malaria is well known in Southeast Asia, the potential for reemergence should receive substantially more attention from economic, agricultural, and environmental planning bodies. Changes in land use and land cover have the potential to facilitate the transmission of disease to humans. Understanding the influence of land use change on malaria occurrence is critical for shaping future surveillance and control strategies.

Acknowledgments

Horst Taraschewski kindly read and commented on the manuscript, and an anonymous reviewer provided useful information.

The National University of Singapore provided support through Young Investigator Award funding (R-109-000-070-123). T.P.'s travel was funded by the Deutsche Forschungsgemeinschaft (PE 11/1-1).

**Trevor Petney,
Paiboon Sithithaworn,
Rojchai Satrawaha,
Carl Grundy-Warr,
Ross Andrews, Yi-Chen Wang,
and Chen-Chieh Feng**

Author affiliations: University of Karlsruhe, Karlsruhe, Germany (T. Petney); Khon Kaen University, Khon Kaen, Thailand (P. Sithithaworn); Mahasarakham University, Mahasarakham, Thailand (R. Satrawaha); National University of Singapore, Singapore (C. Grundy-Warr, Y.-C. Wang, C.-C. Feng); and University of South Australia, Adelaide, South Australia, Australia (R. Andrews)

DOI: 10.3201/eid1508.090240

References

1. van Beilen JB, Poirier Y. Establishment of new crops for the production of natural rubber. *Trends Biotechnol.* 2007;25:522–9.
2. Food and Agriculture Organization. Selected indicators of food and agriculture development in Asia Pacific Region 1992–2002. Bangkok: The Organization; 2003.
3. Rubber Research Institute of Thailand [in Thai] [cited 2009 Jun 24]. Available from <http://www.rubberthai.com>
4. Wright H. *Hevea brasiliensis*, or para rubber, its botany, cultivation, chemistry and diseases, 2nd ed. Colombo (Sri Lanka): A.M. & J. Ferguson; 1906.
5. Chareonviriyaphap T, Bangs MJ, Ratanatham S. Status of malaria in Thailand. *Southeast Asian J Trop Med Public Health.* 2000;31:225–37.
6. Obsomer V, Defourny P, Coosemans M. The *Anopheles dirus* complex: spatial distribution and environmental drivers. *Malar J.* 2007;6:26. DOI: 10.1186/1475-2875-6-26
7. Thimasarn K, Jatapadma S, Vijaykadga S, Sirichaisinthop J, Wongsrichanalai C. Epidemiology of malaria in Thailand. *J Travel Med.* 1995;2:59–65. DOI: 10.1111/j.1708-8305.1995.tb00627.x
8. Yasuoka J, Levins R. Impact of deforestation and agricultural development on anopheline ecology and malaria epidemiology. *Am J Trop Med Hyg.* 2007;76:450–60.
9. Lindblade KA, Walker ED, Onapa AW, Katungu J, Wilson ML. Land use change alters malaria transmission parameters by modifying temperature in a highland area of Uganda. *Trop Med Int Health.* 2000;5:263–74. DOI: 10.1046/j.1365-3156.2000.00551.x
10. Fantini B. Anophelism without malaria: an ecological and epidemiological puzzle. *Parassitologia.* 1994;36:83–106.

Address for correspondence: Trevor Petney, Institute of Zoology I: Ecology and Parasitology, University of Karlsruhe, Kornblumen Strasse 13, Karlsruhe, Germany; email: trevor.petney@bio.uka.de

Fatal Borreliosis in Bat Caused by Relapsing Fever Spirochete, United Kingdom

To the Editor: Tick-borne relapsing fevers caused by members of the genus *Borrelia* have been encountered throughout Africa, Asia, the Americas and, rarely, in southern Europe (1). The *Borrelia* species associated with relapsing fevers form a monophyletic group within the genus, although not all members of this group have yet been implicated as agents of human disease. For example, a novel spirochete that is closely related to the relapsing fever agent *Borrelia turicatae* has recently been detected in *Carios kelleyi*, an argasid bat tick (2,3). We report the discovery of a spirochete causing fatal borreliosis in a bat in the United Kingdom.

The infected bat was a juvenile female *Pipistrellus* species that was found alive but on the ground near the town of Mevagissey in southwestern England in August 2008; despite rehabilitation efforts, it died a few days later. A postmortem examination showed pale skeletal muscles, anemia, excess blood-tinged pleural fluid, a healthy thymus, but enlarged cranial thoracic lymph nodes. The liver was greatly enlarged and mottled, the spleen was also large and unusually dark, and the adrenal glands were enlarged and pale with areas of hemorrhage. The kidneys were pale with a fine speckling

pattern over the cortex. Histopathologic examination of the liver showed multifocal necrosis and vacuolation of hepatocytes and infiltration by macrophages. The lungs were congested and infiltrated by inflammatory cells, and large numbers of granulocytes were found in the blood vessels. The spleen showed marked extramedullary hemopoiesis. Tissue sections stained by the Warthin-Starry technique exhibited numerous long, undulating, argophilic bacilli. These organisms were present in large numbers in the liver lesions (Figure), but were also found in the parenchyma of lung and spleen and in blood vessels.

On the basis of these observations, a diagnosis of fatal hepatitis and septicemia caused by a spirochete was made. DNA from the bat's liver was extracted and analyzed by using a PCR specific for an almost complete fragment of the 16S rRNA-encoding gene, as previously described (4), but with an annealing temperature of

45°C. This DNA extract was also incorporated into PCR assays targeting *glpQ* and *flaB* gene fragments (5). The products of these reactions were sequenced, and sequence data were assembled and analyzed by using Staden (6) and MEGA (7).

We obtained unambiguous sequence data for all 3 loci, comprising of 1,364 bp of the 16S rRNA-encoding gene (GenBank accession no. FJ868583), 1,239 bp of *flaB* and flanking regions (GenBank accession no. FJ868584), and 480 bp of *glpQ* (GenBank accession no. FJ868585). Each of these was aligned with homologous sequences available for other *Borrelia* species and used for phylogenetic analyses. Inferences made by using all loci were congruent, with the UK bat-associated spirochete lying close to, but distinct from, a cluster containing *B. recurrentis*, *B. duttonii*, and *B. crocidurae* (Figure; data not shown).

These 3 species are associated with relapsing fevers in Africa and

Asia. The UK bat-associated spirochete bore no specific evolutionary relatedness to *B. johnsonii*, the newly characterized member of the relapsing fever group of *Borrelia* species associated with *C. kellyi* in the United States (Figure) (3). An *Argas vespertilionis* larval tick was found attached to the infected bat and may have been the source of its infection. PCR was not performed on the tick because it was near-replete with blood that was intensely infected with spirochetes. *A. vespertilionis*, commonly known as the short-legged bat tick, is widely distributed, parasitizing numerous bat species across Europe, southern Asia, and North Africa (8).

Given the close relationship between the novel spirochete we encountered and known pathogens, the reported propensity of *A. vespertilionis* to bite humans (9), and the wide geographic range of this tick, our findings have repercussions for public health in many parts of the Old World. Furthermore, although bats are likely the reservoir host for this organism, our study also identifies it as a pathogen, and as such its discovery has implications for the conservation of numerous threatened bat species across Europe and throughout the world.

Nicholas J. Evans, Kevin Bown, Dorina Timofte, Vic R. Simpson, and Richard J. Birtles

Author affiliations: University of Liverpool, Liverpool, UK (N.J. Evans, K. Bown, D. Tomifte, R.J. Birtles); and Wildlife Veterinary Investigation Centre, Truro, UK (V.R. Simpson)

DOI: 10.3201/eid1508.090475

References

- Rebaudet S, Parola P. Epidemiology of relapsing fever borreliosis in Europe. *FEMS Immunol Med Microbiol*. 2006;48:11–5. DOI: 10.1111/j.1574-695X.2006.00104.x
- Gill JS, Ullmann AJ, Loftis AD, Schwan TG, Raffel SJ, Schrupf ME, et al. Novel relapsing fever spirochete in bat tick. *Emerg Infect Dis*. 2008;14:522–3. DOI: 10.3201/eid1403.070766




Figure. A) Warthin-Starry-stained section of bat liver showing numerous spirochetes. B) Phylogram inferred from 776-bp alignment of *flaB* fragments obtained from infected bat liver tissue and for other members of the relapsing fever group of *Borrelia* species for which sequence data were available. *B. burgdorferi* is included as an outgroup. The numbers appearing after the names of the *Borrelia* species are the relevant GenBank accession numbers. Scale bar indicates nucleotides substitutions per site.

3. Schwan TG, Raffel SJ, Schrupf ME, Gill JS, Piesman J. Characterization of a novel relapsing fever spirochete in the midgut, coxal fluid, and salivary glands of the bat tick *Carios kelleyi*. *Vector Borne Zoonotic Dis.* 2009; [Epub ahead of print].
4. Evans NJ, Brown JM, Demirkan I, Singh P, Getty B, Timofte D, et al. Association of unique, isolated treponemes with bovine digital dermatitis lesions. *J Clin Microbiol.* 2009;47:689–96. DOI: 10.1128/JCM.01914-08
5. Schwan TG, Raffel SJ, Schrupf ME, Policastro PF, Rawlings JA, Lane RS, et al. Phylogenetic analysis of the spirochetes *Borrelia parkeri* and *Borrelia turcatae* and the potential for tick-borne relapsing fever in Florida. *J Clin Microbiol.* 2005;43:3851–9. DOI: 10.1128/JCM.43.8.3851-3859.2005
6. Staden R. The Staden sequence analysis package. *Mol Biotechnol.* 1996;5:233–41. DOI: 10.1007/BF02900361
7. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. *Mol Biol Evol.* 2007;24:1596–9. DOI: 10.1093/molbev/msm092
8. Hillyard PD. Ticks of north-west Europe. Shrewsbury (UK): Field Studies Council; 1996.
9. Jaenson TG, Talleklint L, Lundqvist L, Olsen B, Chirico J, Mejlon H. Geographical distribution, host associations and vector roles of ticks (Acari, Ixodidae, Argasidae) in Sweden. *J Med Entomol.* 1994;31:240–58.

Address for correspondence: Richard J. Birtles, University of Liverpool, Faculty of Veterinary Science, Leahurst Campus, Chester High Road, Cheshire CH64 7TE, UK; email rjbirt@liv.ac.uk

Past, Present, and Future of Japanese Encephalitis

To the Editor: We are writing in response to the perspective on Japanese encephalitis (JE) by Erlanger et al. (1). Growing awareness is encouraging, yet because JE is a largely neglected disease, information is often contradictory or not readily available. We

would like to supplement the authors' review with clarification on available vaccines and actions countries are taking to evaluate and control JE.

There is room for improvement or expansion on collecting and reporting JE surveillance data. However, as vaccine availability increases, many countries are eager to determine the impact of JE and to make informed decisions on immunization programs. For example, surveillance in Indonesia from 2005 through 2006 confirmed human cases throughout the country (2). In Cambodia, JE surveillance commenced in 2006, and an immunization program is being planned (2). Regional JE laboratory networks established by the World Health Organization are also helping countries gather this information by strengthening diagnostic capacity.

Cambodia plans to introduce the live, attenuated SA 14-14-2 vaccine from China's Chengdu Institute of Biological Products. This vaccine has recently become internationally available and is increasingly replacing the inactivated, mouse brain-derived vaccine in Asia. A single dose of the SA 14-14-2 vaccine demonstrated 96% efficacy after 5 years (3), and the Institute's commitment to an affordable price for developing countries has broadened accessibility (4). The government of India introduced the SA 14-14-2 vaccine in 2006, and nearly 50 million children 1–15 years of age have been reached through vaccination campaigns and routine immunization. The vaccine also is available through public programs or private markets in China, Nepal, South Korea, Sri Lanka, and Thailand.

JE vaccine candidates in late-stage development for children include a live, attenuated chimeric virus vaccine and an inactivated, Vero cell-derived vaccine, each based on the SA 14-14-2 virus strain. Additionally, 2 inactivated, Vero-cell derived vaccines based on the Beijing-1 strain are being developed in Japan (5).

New vaccine development, along with progress in surveillance and immunization, offers promise for sustainable control of clinical JE. To achieve this, global partners are working together to develop a strategic plan for JE control by 2015 (6).

**Susan L. Hills
and Deborah C. Phillips**

Author affiliation: PATH, Seattle, WA, USA

DOI: 10.3201/eid1508.090149

References

1. Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. *Emerg Infect Dis.* 2009;15:1–7. DOI: 10.3201/eid1501.080311
2. World Health Organization. Third Bi-regional Meeting on Control of Japanese Encephalitis; 2007 Apr 26–27; Ho Chi Minh City, Vietnam. Manila: World Health Organization Regional Office for the Western Pacific; 2007 [cited 2009 Jan 15]. Available from http://www.wpro.who.int/NR/rdonlyres/50129D1D-E9B3-4707-A62E-0A541DBC3032/0/MTGRPT_JE-Bireg3.pdf
3. Tandan JB, Ohrr H, Sohn YM, Yoksan S, Ji M, Nam CM, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. *Vaccine.* 2007;25:5041–5. DOI: 10.1016/j.vaccine.2007.04.052
4. World Health Organization. Sixteenth Meeting of the Technical Advisory Group on Immunization and Vaccine Preventable Diseases in the Western Pacific Region; 2006 Jun 20–22; Manila, Philippines. Manila: World Health Organization Regional Office for the Western Pacific; 2006 [cited 2009 Jan 15]. Available from http://www.wpro.who.int/NR/rdonlyres/1B75A8B9-2F00-4559-9A1F-C55C24A69304/0/MT-GRPT_TAG16.pdf
5. Beasley DWC, Lewthwaite P, Solomon T. Current use and development of vaccines for Japanese encephalitis. *Expert Opin Biol Ther.* 2008;8:95–106. DOI: 10.1517/14712598.8.1.95
6. Elias C, Okwo-Bele J, Fischer M. A strategic plan for Japanese encephalitis control by 2015. *Lancet Infect Dis.* 2009;9:7. DOI: 10.1016/S1473-3099(08)70290-1

Address for correspondence: Susan L. Hills, PATH, 1455 NW Leary Way, Seattle, WA 98107, USA; email: shills@cdc.gov